Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with
imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their
Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase
(CML-CP).